|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INS |
Gene summary for INS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INS | Gene ID | 3630 |
| Gene name | insulin | |
| Gene Alias | IDDM | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | I3WAC9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3630 | INS | HTA12-15-2 | Human | Pancreas | PDAC | 4.21e-07 | 6.33e-01 | 0.2315 |
| 3630 | INS | HTA12-16-5 | Human | Pancreas | PDAC | 1.34e-09 | 5.46e-01 | 0.047 |
| 3630 | INS | HTA12-29-1 | Human | Pancreas | PDAC | 1.10e-17 | 5.45e-01 | 0.3722 |
| 3630 | INS | HTA12-9-1 | Human | Pancreas | PDAC | 1.54e-02 | 3.32e-01 | 0.1532 |
| 3630 | INS | HTA12-9-2 | Human | Pancreas | PDAC | 3.02e-06 | -8.82e-01 | 0.0835 |
| 3630 | INS | 3829-EC | Human | Pancreas | PanIN | 3.51e-44 | 7.24e-01 | 0.009 |
| 3630 | INS | 4347-EC | Human | Pancreas | PanIN | 4.13e-187 | 1.20e+00 | 0.0572 |
| 3630 | INS | 4741-EC1 | Human | Pancreas | PanIN | 1.43e-45 | 8.66e-01 | 0.0223 |
| 3630 | INS | 181429 | Human | Pancreas | PDAC | 1.38e-04 | -1.64e+00 | 0.1416 |
| 3630 | INS | DS20191261Tumor | Human | Pancreas | PDAC | 1.19e-32 | -1.64e+00 | 0.1367 |
| 3630 | INS | DS20191261TumorKeller | Human | Pancreas | PDAC | 1.12e-06 | -1.64e+00 | 0.1407 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00517016 | Stomach | GC | biological process involved in interaction with host | 29/1159 | 203/18723 | 2.19e-05 | 6.53e-04 | 29 |
| GO:0006633 | Stomach | GC | fatty acid biosynthetic process | 25/1159 | 163/18723 | 2.36e-05 | 6.90e-04 | 25 |
| GO:00425935 | Stomach | GC | glucose homeostasis | 34/1159 | 258/18723 | 2.54e-05 | 7.31e-04 | 34 |
| GO:00335005 | Stomach | GC | carbohydrate homeostasis | 34/1159 | 259/18723 | 2.76e-05 | 7.80e-04 | 34 |
| GO:00462096 | Stomach | GC | nitric oxide metabolic process | 16/1159 | 81/18723 | 3.09e-05 | 8.48e-04 | 16 |
| GO:20010576 | Stomach | GC | reactive nitrogen species metabolic process | 16/1159 | 82/18723 | 3.62e-05 | 9.51e-04 | 16 |
| GO:00469396 | Stomach | GC | nucleotide phosphorylation | 18/1159 | 101/18723 | 4.33e-05 | 1.06e-03 | 18 |
| GO:00620124 | Stomach | GC | regulation of small molecule metabolic process | 40/1159 | 334/18723 | 4.84e-05 | 1.15e-03 | 40 |
| GO:0042632 | Stomach | GC | cholesterol homeostasis | 17/1159 | 96/18723 | 7.61e-05 | 1.64e-03 | 17 |
| GO:00060665 | Stomach | GC | alcohol metabolic process | 41/1159 | 353/18723 | 7.85e-05 | 1.68e-03 | 41 |
| GO:0055092 | Stomach | GC | sterol homeostasis | 17/1159 | 97/18723 | 8.70e-05 | 1.81e-03 | 17 |
| GO:0055088 | Stomach | GC | lipid homeostasis | 24/1159 | 167/18723 | 9.86e-05 | 2.00e-03 | 24 |
| GO:00061656 | Stomach | GC | nucleoside diphosphate phosphorylation | 17/1159 | 99/18723 | 1.13e-04 | 2.16e-03 | 17 |
| GO:00801646 | Stomach | GC | regulation of nitric oxide metabolic process | 13/1159 | 64/18723 | 1.25e-04 | 2.36e-03 | 13 |
| GO:00463944 | Stomach | GC | carboxylic acid biosynthetic process | 37/1159 | 314/18723 | 1.28e-04 | 2.41e-03 | 37 |
| GO:00434675 | Stomach | GC | regulation of generation of precursor metabolites and energy | 20/1159 | 130/18723 | 1.43e-04 | 2.64e-03 | 20 |
| GO:00516516 | Stomach | GC | maintenance of location in cell | 28/1159 | 214/18723 | 1.44e-04 | 2.65e-03 | 28 |
| GO:00160534 | Stomach | GC | organic acid biosynthetic process | 37/1159 | 316/18723 | 1.46e-04 | 2.67e-03 | 37 |
| GO:0042304 | Stomach | GC | regulation of fatty acid biosynthetic process | 11/1159 | 49/18723 | 1.61e-04 | 2.85e-03 | 11 |
| GO:00313316 | Stomach | GC | positive regulation of cellular catabolic process | 46/1159 | 427/18723 | 1.79e-04 | 3.12e-03 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | IDC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Precancer |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Precancer |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | CRC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | FAP |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | MSI-H |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | MSS |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | AEH |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | EEC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Endometrium | Healthy |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | Esophagus | ESCC |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | GC | ADJ |
| NAMPT | INSR | NAMPT_INSR | VISFATIN | GC | GC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |